Production of lentiviral vectors with enhanced efficiency to target dendritic cells by attenuating mannosidase activity of mammalian cells
© Tai et al; licensee BioMed Central Ltd. 2011
Received: 5 October 2010
Accepted: 28 January 2011
Published: 28 January 2011
Dendritic cells (DCs) are antigen-presenting immune cells that interact with T cells and have been widely studied for vaccine applications. To achieve this, DCs can be manipulated by lentiviral vectors (LVs) to express antigens to stimulate the desired antigen-specific T cell response, which gives this approach great potential to fight diseases such as cancers, HIV, and autoimmune diseases. Previously we showed that LVs enveloped with an engineered Sindbis virus glycoprotein (SVGmu) could target DCs through a specific interaction with DC-SIGN, a surface molecule predominantly expressed by DCs. We hypothesized that SVGmu interacts with DC-SIGN in a mannose-dependent manner, and that an increase in high-mannose structures on the glycoprotein surface could result in higher targeting efficiencies of LVs towards DCs. It is known that 1-deoxymannojirimycin (DMJ) can inhibit mannosidase, which is an enzyme that removes high-mannose structures during the glycosylation process. Thus, we investigated the possibility of generating LVs with enhanced capability to modify DCs by supplying DMJ during vector production.
Through western blot analysis and binding tests, we were able to infer that binding of SVGmu to DC-SIGN is directly related to amount of high-mannose structures on SVGmu. We also found that the titer for the LV (FUGW/SVGmu) produced with DMJ against 293T.DCSIGN, a human cell line expressing the human DC-SIGN atnibody, was over four times higher than that of vector produced without DMJ. In addition, transduction of a human DC cell line, MUTZ-3, yielded a higher transduction efficiency for the LV produced with DMJ.
We conclude that LVs produced under conditions with inhibited mannosidase activity can effectively modify cells displaying the DC-specific marker DC-SIGN. This study offers evidence to support the utilization of DMJ in producing LVs that are enhanced carriers for the development of DC-directed vaccines.
Dendritic cells (DCs) are immune cells that are able to present antigens to T cells in a major histocompatibility complex (MHC)-restricted manner. These antigens are usually obtained by phagocytosis of pathogens encountered by the DCs . The naive T cells are activated by the interaction with the antigen-presenting DCs and are then able to recognize the corresponding pathogens. To utilize this mechanism for therapeutic applications such as immunizations and vaccinations, DCs can be loaded with antigens to stimulate antigen-specific CD8+ and CD4+ T cell responses [1–4]. Another method of modifying DCs to present desired antigens is to genetically alter the cells by using liposomes or gene-gun, or by viral transduction with replication-incompetent viral vectors [5, 6]. The benefits of these strategies are the increased time of antigen presentation, the ability to present both MHC I and II epitopes, and the ability to include genes for immomodulatory molecules that may enhance DC function . Currently, adenoviral, gamma-retrovial, and lentiviral vectors (LVs) are studied for the viral vector delivery strategy [8–11]. LVs pose an advantage in their ability to transduce non-dividing cells, which is beneficial for in vivo immunization [12–16]. However, these recombinant viral vectors are known to have broad specificity and are able to transduce multiple cell types, which can inevitably result in genetic modification of undesired cells and reduce vaccine efficacy [17, 18].
A surface molecule present on immature DCs, Dendritic Cell-specific ICAM3-grabbing Nonintegrin (DC-SIGN), is well-displayed and a suitable target for DC-specific transduction [18, 19]. DC-SIGN is a C-type (Ca2+-dependent) lectin that is able to rapidly bind to and endocytose antigenic materials . It is a type II transmembrane protein that is displayed as a tetramer, and consists of a short, N-terminal cytoplasmic tail that contains intracellular sorting motifs, a transmembrane region, an extracellular stalk, and a C-terminal carbohydrate-recognition domain (CRD) [21–23]. It was reported that the Sindbis virus (SV), a member of the alphavirus genus and the Togaviridae family, is able to recognize and bind to DCs through DC-SIGN . However, the SV glycoprotein (SVG) also has the ability to bind to cell-surface heparin sulfate (HS), which is expressed by many cell types, and therefore LVs pseudotyped with SVG have a broad tropism [25, 26]. Further studies showed that the HS binding site of SVG can be mutated  so that the resulting SVGmu glycoprotein can selectively recognize and bind to DC-SIGN . Thus, SVGmu-pseudotyped LVs can specifically target and recognize DCs, delivering antigens that enable T cell activation for immunization and vaccine purposes [28–30].
Results and Discussion
Transient transfection of 293T cells to produce SVGmu-pseudotyped LVs
Verification of SVGmu and high-mannose oligosaccharides on the vector surface
Evaluation of cell-vector binding to DC-SIGN
Next, a radioactive-labeling assay was used to test the cell-vector binding responses for LVs produced with and without DMJ, with an additional comparison to control 293T cells, which lacked DC-SIGN expression. 293T and 293T.DCSIGN cells were seeded onto 96-well plates overnight. The cells were then washed by PBS and incubated with concentrated, 35S-labeled LVs for one hour. A second wash with PBS removed unbound vectors and the cells were lysed before they were pipetted into scintillation vials for analysis. A mannose inhibition assay was also employed to test the dependency of vector binding on the mannose-rich structures of the envelope glycoprotein. Mannose was incubated with the cells prior to the addition of LVs to block the binding sites that are mannose-linked. A much higher amount of radioactivity was detected in FUGW/SVGmu(DMJ+) incubated with 293T.DCSIGN as compared to FUGW/SVGmu(DMJ-) (Figure 5B). In contrast, DMJ did not greatly alter the binding ability of FUGW/SVGmu to 293T cells; vectors produced with and without DMJ resulted in a low incidence of binding. Although the addition of mannose lowered the amount of cell-vector binding measured with both types of LVs (DMJ+ and DMJ-) and both types of cells (293T.DCSIGN and 293T), it had the most significant effect on the binding of FUGW/SVGmu(DMJ+) to the 293T.DCSIGN cells. This data suggests that the enhanced ability of the LV to bind to DC-SIGN we observed was the result of its greater availability of high-mannose structures, and that this interaction can be blocked by competitive inhibition with mannose.
Transduction of cells with LVs produced with DMJ
Vector titers were then calculated for FUGW/SVGmu +/- DMJ against 293T and 293T.DCSIGN cells. FUGW/VSVG +/- DMJ were also included as controls. Triplicate experiments were performed, where cells were spin-infected with various fresh vector supernatants that had been serially diluted. Three days later, the cells were washed and analyzed for GFP expression by flow cytometry. As expected, FUGW/SVGmu(DMJ+) yielded a higher transduction titer with 293T.DCSIGN cells, with an average value of 0.26 × 106 TU/ml, as compared to FUGW/SVGmu(DMJ-), which had an average transduction titer of 0.08 × 106 TU/ml (Figure 6B). FUGW/SVGmu +/- DMJ both transduced 293T cells similarly with titers of ~0.04 × 106 TU/ml. As an additional control, 293T.DCSIGN cells were also tranduced by FUGW/VSVG +/- DMJ and titers of 22.60 × 106 TU/ml and 24.60 × 106 TU/ml, respectively, were obtained. Thus, our titer measurement confirms that FUGW/SVGmu(DMJ+) transduced 293T.DCSIGN cells three times more efficiently than FUGW/SVGmu(DMJ-) did, and that both FUGW/SVGmu +/- DMJ transduced 293T cells at an equally low rate. The addition of DMJ to the production of the FUGW/VSVG vector did not significantly alter the vector titer against 293T.DCSIGN.
One group demonstrated that LVs pseudotyped with a similarly modified Sindbis virus envelope glycoprotein produced without DMJ treatment did not bind to DC-SIGN and target DC-SIGN-positive cells . The mutations used in their envelope protein were identical except for the addition of a ZZ domain versus the HA tag employed in our system. However, previous studies in our laboratory have shown that SVGmu binds with DC-SIGN and targets transduction to DC-SIGN-positive cells . Also, compared with our data for wild-type Sindbis envelope-bearing LVs, their pseudotyped vectors are less infectious (Virus-receptor mediated transduction of dendritic cells by lentiviruses enveloped with glycoproteins derived from Semliki Forest virus and Ross River virus, submitted). Perhaps these differences in infectious vector production are indicative of an abundance of non-infectious particles that conceal interactions between the glycoprotein and DC-SIGN. Other differences, such as our use of a clonally-expanded DC-SIGN-expressing cell line and other experimental settings, may further contribute to the reported inability to observe increased transduction efficiencies for DC-SIGN bearing cell lines with SVGmu envelope-bearing LVs produced without DMJ.
Transduction of a DC cell line with vectors produced with DMJ
DC-based vaccines have great potential as a new means to fight challenging diseases, such as cancers, HIV, and autoimmune diseases. Optimization of the efficiency of the viral vectors used to modify DCs could greatly strengthen this approach and make it an even more powerful tool for developing novel treatment modalities against various diseases. Our study aimed to examine the effects of DMJ, which indirectly increases the amount of high-mannose structures present on glycoproteins through the inhibition of class I α1,2-mannosidase activity in vector-producing cells, on the efficiency of SVGmu-bearing LV transduction of DC-SIGN-expressing cells.
We were able to conclude that the FUGW/SVGmu vector made in the presence of DMJ did in fact have increased high-mannose structures over those made without DMJ present. Our results also suggested that binding of SVGmu to DC-SIGN is directly related to amount of high-mannose structures on SVGmu, and that these interactions can be blocked by competitive inhibition. Furthermore, we found that production of the targeting vector in DMJ resulted in a three-fold increase in transduction efficiency in target cells compared to vectored produced without DMJ. Lastly, the targeting vector produced in the presence of DMJ was able to transduce MUTZ-3 cells, a cell line that has been shown to closely mimic the behavior of human peripheral blood mononuclear cells (PBMCs) and can be differentiated to cells displaying DC-SIGN, more efficiently than the vector produced without DMJ, which strengthens our belief that an increase in high-mannose structures on the targeting virus surface would result in higher transduction efficiency of human DCs.
Further investigation into the vector entry mechanism of SVGmu-pseudotyped LVs is currently being conducted using confocal microscopy with the aid of drug treatments. Greater understanding of the pathway of viral uptake and core release into the cytosol will facilitate the design of more effective and efficient engineered gene delivery vehicles. Additionally, siRNA can be applied to silence mannosidase in vector-producing cells to eliminate the need for DMJ in large-scale productions of optimized high-mannose-containing engineered LVs.
Production of lentiviral vectors
293T cells were transiently transfected with a standard calcium phosphate precipitation protocol. 293T cells were seeded onto 6-cm tissue culture dishes and transfected with 5 μg of the lentiviral transfer vector plasmid (FUGW or FUW), 2.5 μg of the envelope plasmid (SVGmu or VSVG), and packaging plasmids (pMDLg/pRRE and pRSV-Rev). D10 media (Dulbecco's modified Eagle's medium (Mediatech Inc., Manassas, VA) with 10% fetal bovine serum (Sigma, St. Louis, MO), 2 mM L-glutamine (Hyclone, Logan, UT), 100 U/ml penicillin, and 100 μg/ml streptomycin) with and without DMJ was replaced 4 h later. After 48 h post-transfection, the vector supernatants were harvested and filtered through a 0.45-μm filter (Corning, Acton, MA). To concentrate the vector, the supernatants were ultracentrifugated (Optima L-80 K preparative ultracentrifuge, Beckman Coulter, Brea, CA) after filtration at 50,000 × g for 90 min. The viral pellets were resuspended in 100 μl of cold PBS.
Confocal imaging of lentiviral vectors
LVs were produced with the addition of 2.5 μg of a plasmid encoding GFP-Vpr. Vector supernatant was placed on polylysine-coated coverslips in 6-well culture dishes and centrifuged at 3,700 × g at 4°C for 2 h with a Sorvall Legend RT centrifuge (DJB Labcare, Buckinghamshire, England). The coverslips were then washed twice with cold PBS and immunostained with anti-HA-biotin antibody (Miltenyi Biotec, Bergisch Gladbach, Germany) and Cy5-streptavidin (Invitrogen, Carlsbad, CA). The samples were fluorescently imaged by a Zeiss LSM 510 laser scanning confocal microscope with filter sets for fluorescein and Cy5 and a plan-apochromat oil immersion objective (63×/1.4).
Vector digestion by EndoH and western blot
7 μl of concentrated virus was combined with 2 μl of lysis buffer and incubated at 37°C for 30 min. Next, the glycoprotein was denatured by adding 1 μl of 10× Glycoprotein Denaturing Buffer to the mixture and heating the reaction to 100°C for 10 min. The protein was then digested by EndoH by adding 2 μl of 10 × G5 Reaction Buffer, 5 μl of EndoH (NEB, Ipswich, MA), and 3 μl of H2O. This reaction was incubated at 37°C for 1 h. Protein gels were run and then western blots were performed to transfer the proteins onto membranes. The membranes were then blocked by 5% milk with TBST at 4°C for 1 h. The membranes were washed with TBST and then stained for anti-HA-biotin antibody for 1 h. They were then washed again, stained for streptavidin-HRP (R&D Systems, Minneapolis, MN) for 1 hr, and washed. To develop the western blot, TMB solution was spread onto the surface of the membrane and left for 10 min at room temperature. The membrane was then imaged.
Radioactive labeling and mannose inhibition of lentiviral vectors
293T cells were transfected by vector plasmids as described earlier, without the addition of DMJ. 20 h post-transfection, the media was replaced with methionine-free D10 with or without DMJ. After 4 h, 50 μl of [35S]-Trans (MP Biochemicals, Solon, OH) was added to 15-cm tissue culture dishes and incubated at 37°C. 48 h post-tranfection, viral supernatants were harvested, filtered, and concentrated. For the mannose inhibition assay, 10 mM of D-mannose was added to the 293T.hDCSIGN cells prior to the cell-virus binding tests.
Vector transduction of cells
293T or 293T.DCSIGN cells were seeded into a 24-well culture dish at 0.2 × 106 cells per well and spin-infected with 1 ml of viral supernatant per well at 2,500 rpm and 25°C for 90 min using a Sorvell Legend centrifuge. The cell supernatants were then replaced with fresh D10 media and incubated at 37°C for 3 days with 5% CO2. FACS analysis was used to determine the percentage of GFP+ cells present. To determine transduction titers, the dilution ranges that showed a linear response were used.
Transduction of a human DC cell line
MUTZ-3 cells (Deutsche Sammlung von Mikroorganismen und Zellkulturen, Braunschweig, Germany) were cultured in 24-well tissue culture plates in αMEM media (BioWhittaker, Walkersville, MD) with 20% FBS (Sigma-Aldrich, St. Louis, MO) and 40 ng/mL GM-CSF (PeproTech, Rocky Hill, NJ). To differentiate the cells to express human DC-SIGN, MUTZ-3 cells were cultured in the presence of IL-4 and GM-CSF (100 ng/mL of each; PeproTech) for 7 days. FACS analysis of cells stained with anti-human DCSIGN-PE (BioLegend, San Diego, CA) confirmed the presence of the human DC-SIGN marker. The cells (1 × 105) were spin-infected with concentrated virus and the medium was replaced with fresh medium containing IL-4 and GM-CSF. The cells were analyzed by flow cytometry for GFP expression 3 days post-tranduction.
lentiviral vector carrying a GFP reporter gene under the control of the human ubiquitin C promoter
green fluorescent protein
GFP fused to the N-terminus of Vpr
major histocompatibility complex
Sindbis virus glycoprotein
the HIV accessory protein viral protein R
vesicular stomatitis viral glycoprotein.
We thank Chi-Lin Lee for the preparation of figures. This work was supported by a National Institute of Health grant R01-AI068978.
- Mellman I, Steinman RM: Dendritic cells: specialized and regulated antigen processing machines. Cell 2001, 106: 255-258. 10.1016/S0092-8674(01)00449-4View ArticleGoogle Scholar
- Steinman RM, Banchereau J: Taking dendritic cells into medicine. Nature 2007, 449: 419-426. 10.1038/nature06175View ArticleGoogle Scholar
- Banchereau J, Steinman RM: Dendritic cells and the control of immunity. Nature 1998, 392: 245-252. 10.1038/32588View ArticleGoogle Scholar
- Banchereau J, Briere F, Caux C, Davoust J, Lebecque S, Liu YJ, Pulendran B, Palucka K: Immunobiology of dendritic cells. Annual review of immunology 2000, 18: 767-811. 10.1146/annurev.immunol.18.1.767View ArticleGoogle Scholar
- Figdor CG, de Vries IJ, Lesterhuis WJ, Melief CJ: Dendritic cell immunotherapy: mapping the way. Nat Med 2004, 10: 475-480. 10.1038/nm1039View ArticleGoogle Scholar
- Breckpot K, Heirman C, Neyns B, Thielemans K: Exploiting dendritic cells for cancer immunotherapy: genetic modification of dendritic cells. J Gene Med 2004, 6: 1175-1188. 10.1002/jgm.615View ArticleGoogle Scholar
- Ribas A, Butterfield LH, Glaspy JA, Economou JS: Cancer immunotherapy using gene-modified dendritic cells. Current gene therapy 2002, 2: 57-78. 10.2174/1566523023348129View ArticleGoogle Scholar
- Draper SJ, Heeney JL: Viruses as vaccine vectors for infectious diseases and cancer. Nat Rev Microbiol 2010, 8: 62-73. 10.1038/nrmicro2240View ArticleGoogle Scholar
- Gardlik R, Palffy R, Hodosy J, Lukacs J, Turna J, Celec P: Vectors and delivery systems in gene therapy. Med Sci Monit 2005, 11: RA110-121.Google Scholar
- Schaffer DV, Koerber JT, Lim KI: Molecular engineering of viral gene delivery vehicles. Annu Rev Biomed Eng 2008, 10: 169-194. 10.1146/annurev.bioeng.10.061807.160514View ArticleGoogle Scholar
- Song W, Kong HL, Carpenter H, Torii H, Granstein R, Rafii S, Moore MA, Crystal RG: Dendritic cells genetically modified with an adenovirus vector encoding the cDNA for a model antigen induce protective and therapeutic antitumor immunity. J Exp Med 1997, 186: 1247-1256. 10.1084/jem.186.8.1247View ArticleGoogle Scholar
- Esslinger C, Chapatte L, Finke D, Miconnet I, Guillaume P, Levy F, MacDonald HR: In vivo administration of a lentiviral vaccine targets DCs and induces efficient CD8(+) T cell responses. J Clin Invest 2003, 111: 1673-1681.View ArticleGoogle Scholar
- Palmowski MJ, Lopes L, Ikeda Y, Salio M, Cerundolo V, Collins MK: Intravenous injection of a lentiviral vector encoding NY-ESO-1 induces an effective CTL response. J Immunol 2004, 172: 1582-1587.View ArticleGoogle Scholar
- Pincha M, Sundarasetty BS, Stripecke R: Lentiviral vectors for immunization: an inflammatory field. Expert Rev Vaccines 2010, 9: 309-321. 10.1586/erv.10.9View ArticleGoogle Scholar
- He Y, Munn D, Falo LD Jr: Recombinant lentivector as a genetic immunization vehicle for antitumor immunity. Expert Rev Vaccines 2007, 6: 913-924. 10.1586/14760518.104.22.1683View ArticleGoogle Scholar
- Lopes L, Dewannieux M, Gileadi U, Bailey R, Ikeda Y, Whittaker C, Collin MP, Cerundolo V, Tomihari M, Ariizumi K, Collins MK: Immunization with a lentivector that targets tumor antigen expression to dendritic cells induces potent CD8+ and CD4+ T-cell responses. J Virol 2008, 82: 86-95. 10.1128/JVI.01289-07View ArticleGoogle Scholar
- Follenzi A, Battaglia M, Lombardo A, Annoni A, Roncarolo MG, Naldini L: Targeting lentiviral vector expression to hepatocytes limits transgene-specific immune response and establishes long-term expression of human antihemophilic factor IX in mice. Blood 2004, 103: 3700-3709. 10.1182/blood-2003-09-3217View ArticleGoogle Scholar
- Tacken PJ, de Vries IJ, Torensma R, Figdor CG: Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting. Nat Rev Immunol 2007, 7: 790-802. 10.1038/nri2173View ArticleGoogle Scholar
- Soilleux EJ, Morris LS, Leslie G, Chehimi J, Luo Q, Levroney E, Trowsdale J, Montaner LJ, Doms RW, Weissman D, et al.: Constitutive and induced expression of DC-SIGN on dendritic cell and macrophage subpopulations in situ and in vitro. J Leukoc Biol 2002, 71: 445-457.Google Scholar
- Lozach PY, Amara A, Bartosch B, Virelizier JL, Arenzana-Seisdedos F, Cosset FL, Altmeyer R: C-type lectins L-SIGN and DC-SIGN capture and transmit infectious hepatitis C virus pseudotype particles. J Biol Chem 2004, 279: 32035-32045. 10.1074/jbc.M402296200View ArticleGoogle Scholar
- Figdor CG, van Kooyk Y, Adema GJ: C-type lectin receptors on dendritic cells and Langerhans cells. Nat Rev Immunol 2002, 2: 77-84. 10.1038/nri723View ArticleGoogle Scholar
- Soilleux EJ: DC-SIGN (dendritic cell-specific ICAM-grabbing non-integrin) and DC-SIGN-related (DC-SIGNR): friend or foe? Clin Sci (Lond) 2003, 104: 437-446. 10.1042/CS20020092View ArticleGoogle Scholar
- Lozach PY, Burleigh L, Staropoli I, Amara A: The C type lectins DC-SIGN and L-SIGN: receptors for viral glycoproteins. Methods Mol Biol 2007, 379: 51-68. full_textView ArticleGoogle Scholar
- Klimstra WB, Nangle EM, Smith MS, Yurochko AD, Ryman KD: DC-SIGN and L-SIGN can act as attachment receptors for alphaviruses and distinguish between mosquito cell- and mammalian cell-derived viruses. J Virol 2003, 77: 12022-12032. 10.1128/JVI.77.22.12022-12032.2003View ArticleGoogle Scholar
- Morizono K, Bristol G, Xie YM, Kung SK, Chen IS: Antibody-directed targeting of retroviral vectors via cell surface antigens. J Virol 2001, 75: 8016-8020. 10.1128/JVI.75.17.8016-8020.2001View ArticleGoogle Scholar
- Cronin J, Zhang XY, Reiser J: Altering the tropism of lentiviral vectors through pseudotyping. Current gene therapy 2005, 5: 387-398. 10.2174/1566523054546224View ArticleGoogle Scholar
- Morizono K, Xie Y, Ringpis GE, Johnson M, Nassanian H, Lee B, Wu L, Chen IS: Lentiviral vector retargeting to P-glycoprotein on metastatic melanoma through intravenous injection. Nat Med 2005, 11: 346-352. 10.1038/nm1192View ArticleGoogle Scholar
- Yang L, Yang H, Rideout K, Cho T, Joo KI, Ziegler L, Elliot A, Walls A, Yu D, Baltimore D, Wang P: Engineered lentivector targeting of dendritic cells for in vivo immunization. Nat Biotechnol 2008, 26: 326-334. 10.1038/nbt1390View ArticleGoogle Scholar
- Dai B, Yang L, Yang H, Hu B, Baltimore D, Wang P: HIV-1 Gag-specific immunity induced by a lentivector-based vaccine directed to dendritic cells. Proc Natl Acad Sci USA 2009, 106: 20382-20387. 10.1073/pnas.0911742106View ArticleGoogle Scholar
- Hu B, Dai B, Wang P: Vaccines delivered by integration-deficient lentiviral vectors targeting dendritic cells induces strong antigen-specific immunity. Vaccine 2010, 28: 6675-6683. 10.1016/j.vaccine.2010.08.012View ArticleGoogle Scholar
- Mitchell DA, Fadden AJ, Drickamer K: A novel mechanism of carbohydrate recognition by the C-type lectins DC-SIGN and DC-SIGNR. Subunit organization and binding to multivalent ligands. J Biol Chem 2001, 276: 28939-28945. 10.1074/jbc.M104565200View ArticleGoogle Scholar
- Geijtenbeek TB, Kwon DS, Torensma R, van Vliet SJ, van Duijnhoven GC, Middel J, Cornelissen IL, Nottet HS, KewalRamani VN, Littman DR, et al.: DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells. Cell 2000, 100: 587-597. 10.1016/S0092-8674(00)80694-7View ArticleGoogle Scholar
- Feinberg H, Mitchell DA, Drickamer K, Weis WI: Structural basis for selective recognition of oligosaccharides by DC-SIGN and DC-SIGNR. Science 2001, 294: 2163-2166. 10.1126/science.1066371View ArticleGoogle Scholar
- Elbein AD: Glycosidase inhibitors: inhibitors of N-linked oligosaccharide processing. FASEB J 1991, 5: 3055-3063.Google Scholar
- Elbein AD, Legler G, Tlusty A, McDowell W, Schwarz R: The effect of deoxymannojirimycin on the processing of the influenza viral glycoproteins. Arch Biochem Biophys 1984, 235: 579-588. 10.1016/0003-9861(84)90232-7View ArticleGoogle Scholar
- Vallee F, Karaveg K, Herscovics A, Moremen KW, Howell PL: Structural basis for catalysis and inhibition of N-glycan processing class I alpha 1,2-mannosidases. J Biol Chem 2000, 275: 41287-41298. 10.1074/jbc.M006927200View ArticleGoogle Scholar
- Balzarini J: The alpha(1,2)-mannosidase I inhibitor 1-deoxymannojirimycin potentiates the antiviral activity of carbohydrate-binding agents against wild-type and mutant HIV-1 strains containing glycan deletions in gp120. FEBS Lett 2007, 581: 2060-2064. 10.1016/j.febslet.2007.04.039View ArticleGoogle Scholar
- Lois C, Hong EJ, Pease S, Brown EJ, Baltimore D: Germline transmission and tissue-specific expression of transgenes delivered by lentiviral vectors. Science 2002, 295: 868-872. 10.1126/science.1067081View ArticleGoogle Scholar
- Joo KI, Wang P: Visualization of targeted transduction by engineered lentiviral vectors. Gene Ther 2008, 15: 1384-1396. 10.1038/gt.2008.87View ArticleGoogle Scholar
- Morizono K, Ku A, Xie Y, Harui A, Kung SK, Roth MD, Lee B, Chen IS: Redirecting lentiviral vectors pseudotyped with Sindbis virus-derived envelope proteins to DC-SIGN by modification of N-linked glycans of envelope proteins. J Virol 2010, 84: 6923-6934. 10.1128/JVI.00435-10View ArticleGoogle Scholar
- Larsson K, Lindstedt M, Borrebaeck CA: Functional and transcriptional profiling of MUTZ-3, a myeloid cell line acting as a model for dendritic cells. Immunology 2006, 117: 156-166. 10.1111/j.1365-2567.2005.02274.xView ArticleGoogle Scholar
- Santegoets SJ, van den Eertwegh AJ, van de Loosdrecht AA, Scheper RJ, de Gruijl TD: Human dendritic cell line models for DC differentiation and clinical DC vaccination studies. J Leukoc Biol 2008, 84: 1364-1373. 10.1189/jlb.0208092View ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.